Cellular and molecular mechanisms of HGF/Met in the cardiovascular system

Clin Sci (Lond). 2015 Dec;129(12):1173-93. doi: 10.1042/CS20150502.

Abstract

Met tyrosine kinase receptor, also known as c-Met, is the HGF (hepatocyte growth factor) receptor. The HGF/Met pathway has a prominent role in cardiovascular remodelling after tissue injury. The present review provides a synopsis of the cellular and molecular mechanisms underlying the effects of HGF/Met in the heart and blood vessels. In vivo, HGF/Met function is particularly important for the protection of the heart in response to both acute and chronic insults, including ischaemic injury and doxorubicin-induced cardiotoxicity. Accordingly, conditional deletion of Met in cardiomyocytes results in impaired organ defence against oxidative stress. After ischaemic injury, activation of Met provides strong anti-apoptotic stimuli for cardiomyocytes through PI3K (phosphoinositide 3-kinase)/Akt and MAPK (mitogen-activated protein kinase) cascades. Recently, we found that HGF/Met is also important for autophagy regulation in cardiomyocytes via the mTOR (mammalian target of rapamycin) pathway. HGF/Met induces proliferation and migration of endothelial cells through Rac1 (Ras-related C3 botulinum toxin substrate 1) activation. In fibroblasts, HGF/Met antagonizes the actions of TGFβ1 (transforming growth factor β1) and AngII (angiotensin II), thus preventing fibrosis. Moreover, HGF/Met influences the inflammatory response of macrophages and the immune response of dendritic cells, indicating its protective function against atherosclerotic and autoimmune diseases. The HGF/Met axis also plays an important role in regulating self-renewal and myocardial regeneration through the enhancement of cardiac progenitor cells. HGF/Met has beneficial effects against myocardial infarction and endothelial dysfunction: the cellular and molecular mechanisms underlying repair function in the heart and blood vessels are common and include pro-angiogenic, anti-inflammatory and anti-fibrotic actions. Thus administration of HGF or HGF mimetics may represent a promising therapeutic agent for the treatment of both coronary and peripheral artery disease.

Keywords: Angiogenesis; Autophagy; Cardiovascular system; HGF/Met; SXS; Signalling; TGF-β/BMP7/Smad pathway fibrosis; angiogenesis; cardioprotection; fibrosis; immunomodulation; regeneration; signalling; signalling pathway.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Autophagy
  • Blood Vessels / drug effects
  • Blood Vessels / enzymology*
  • Blood Vessels / immunology
  • Blood Vessels / pathology
  • Blood Vessels / physiopathology
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / enzymology*
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / immunology
  • Cardiovascular Diseases / pathology
  • Cardiovascular Diseases / physiopathology
  • Dendritic Cells / enzymology
  • Dendritic Cells / immunology
  • Fibrosis
  • Hepatocyte Growth Factor / genetics
  • Hepatocyte Growth Factor / metabolism*
  • Hepatocyte Growth Factor / therapeutic use
  • Humans
  • Immune Tolerance
  • Inflammation / enzymology
  • Inflammation / pathology
  • Inflammation / prevention & control
  • Molecular Targeted Therapy
  • Myocardium / enzymology*
  • Myocardium / immunology
  • Myocardium / pathology
  • Neovascularization, Physiologic
  • Oxidative Stress
  • Proto-Oncogene Proteins c-met / genetics
  • Proto-Oncogene Proteins c-met / metabolism*
  • Regeneration
  • Signal Transduction* / drug effects
  • Vascular Remodeling* / drug effects
  • Ventricular Remodeling* / drug effects

Substances

  • Hepatocyte Growth Factor
  • Proto-Oncogene Proteins c-met